Aethlon Medical
San Diego, California, United States · Biotechnology, Health Care, Medical
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-b
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 24
- Industries
- Biotechnology, Health Care, Medical
- Status
- Public (AEMD)
- Website
- aethlonmedical.com
- Company page
Recent activity at Aethlon Medical
- : Aethlon Medical to merge with North Immunology
- : SEC 8-K (7.01):
- : SEC 8-K (7.01): On November 12, 2026, Aethlon Medical, Inc. issued a press release regarding its financial results for the quarter ended September 30, 2026. This disclosure is related to financial information that is being reported under Regulation FD, which aims to promote fair disclosure of material information. The press release serves to inform investors and the public about the company's performance and is attached as Exhibit 99.1 to the filing. This event is significant as it provides insights into the financial standing of Aethlon Medical as of the recent quarter, impacting investor perception and stock performance.
- : SEC 8-K (5.03): On October 7, 2026, Aethlon Medical, Inc. filed an amendment to its Articles of Incorporation following approval from stockholders at the 2026 Annual Meeting held on October 1, 2026. The amendment increases the number of authorized shares of common stock from 20,000,000 to 200,000,000 shares, thereby significantly boosting the company's capacity to issue additional stock. This change could potentially enhance the company's ability to raise capital and support future growth initiatives, reflecting a strategic decision to expand corporate resources. The Articles Amendment is now effective and formally amends Article V of the Company’s Articles of Incorporation.
- : SEC 8-K (5.02): On October 1, 2026, Aethlon Medical, Inc. held its Annual Meeting of Stockholders, where stockholders approved an amendment to the company’s 2020 Equity Incentive Plan. This amendment increases the number of shares of common stock authorized for issuance under the plan by 100,000 shares. The Board of Directors previously approved this amendment, contingent upon stockholder approval, on July 10, 2026. The effective date for this amendment was also set for October 1, 2026, right after stockholder approval, enhancing the company's capacity to incentivize its employees through stock options.
- : SEC 8-K (1.01): On September 17, 2026, Aethlon Medical, Inc. entered into a Merger Agreement with Nighthawk Merger Sub Corp. and Nighthawk Second Merger Sub, LLC, both wholly owned subsidiaries, to merge with North Immunology, Inc. This strategic move is aimed at expanding Aethlon's capabilities in the medical field, specifically in immunotherapy. The agreement details the procedures for the merger, including the conditions that must be met for the merger to proceed, although specific financial terms are not disclosed in this filing. The completion of the merger is contingent upon various conditions being satisfied or waived as outlined in the agreement.
- : SEC 8-K (5.02): On September 11, 2026, Aethlon Medical, Inc. amended the employment agreements of James B. Frakes, CEO and CFO, and Dr. Steven P. LaRosa, Chief Medical Officer. The amendments include a provision for severance payments to be paid in a lump sum rather than installments if a Change in Control occurs and the executive's employment is terminated under qualifying circumstances. This change impacts the financial arrangements for these executive officers should a transition in control happen, potentially streamlining their severance benefits during such an event.
- : SEC 8-K (8.01): Aethlon Medical, Inc. reported the exercise of certain pre-funded warrants, resulting in a total of 1,604,095 shares of common stock outstanding as of the close of business on August 28, 2026. This indicates that all previously outstanding pre-funded warrants have been fully exercised. The implications of this event include an increase in the company's equity and potential dilution for existing shareholders. The filing highlights both the recent activity and the firm’s current share structure following the warrant exercises.
- : SEC 8-K (7.01): On August 13, 2026, Aethlon Medical, Inc. disclosed its financial results for the quarter ended June 30, 2026, through a press release which is attached as Exhibit 99.1 in this filing. This disclosure is being made under Item 7.01, Regulation FD, and it includes important financial information that will not be considered 'filed' under the Securities Exchange Act. The press release details the company's performance, key metrics, and operational updates relevant for investors. This disclosure aims to ensure compliance with Regulation FD by providing all investors with equal access to the company's financial information.
- : SEC 8-K (1.01): On July 6, 2026, Aethlon Medical, Inc. entered into a Securities Purchase Agreement with certain investors to sell 263,000 shares of common stock, along with various warrants (Common Warrants, Pre-Funded Warrants, and Placement Agent Warrants) for a combined public offering price of $0.71 per share and accompanying warrant. The transaction closed on July 7, 2026. This agreement signifies a strategic move to raise capital through a registered public offering, enhancing the company's liquidity. Maxim Group LLC acted as the placement agent for this transaction, implying a structured approach to the capital raise that could attract more investors.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Aethlon Medical funding history
| Date | Round | Amount |
|---|---|---|
| Dec 2025 | Venture | $2.2M |
| Jan 2020 | Venture | $2.7M |
| Jul 2015 | Venture | $6.0M |
Leadership
- Lee Arnold, President & CEO
- GUY CIPRIANI, Director
- CHETAN SHAH, Director
- CHARLES FISHER, Director
- EDWARD BROENNIMAN, Director
- SABRINA JOHNSON, Director
- TIMOTHY RODELL, Executive Officer, Director
- Steven P. LaRosa, M.D., Chief Medical Officer
- James B. Frakes, Chief Financial Officer
- Steven P. LaRosa, Chief Medical Officer
- Steven Larosa, Chief Medical Officer
Verified email and direct lines for Aethlon Medical’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Aethlon Medical files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Aethlon Medical
- OncoNano Medicine · Biotechnology, Health Care, Medical, Therapeutics
- Imugene · Biotechnology, Health Care, Medical, Therapeutics
- NuCana · Biotechnology, Health Care, Medical, Therapeutics
- Immunocine Cancer Center · Biotechnology, Health Care, Medical, Therapeutics
- Faeth Therapeutics · Biotechnology, Health Care, Medical, Therapeutics
About Aethlon Medical: questions and answers
What does Aethlon Medical do?
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-b
Where is Aethlon Medical headquartered?
Aethlon Medical is headquartered in San Diego, California, United States.
How many employees does Aethlon Medical have?
Aethlon Medical has about 24 employees.
Has Aethlon Medical raised funding?
Yes. Fundz has recorded 3 funding events for Aethlon Medical. The most recent, $2.2M, was in Dec 2025.
Who leads Aethlon Medical?
Lee Arnold is a President & CEO at Aethlon Medical.
What is the latest news on Aethlon Medical?
On Sep 17, 2026, Aethlon Medical to merge with North Immunology
Is Aethlon Medical a public company?
Yes. Aethlon Medical is publicly traded under the ticker AEMD.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy